Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23826018 | 0.89 | FFAR1 (0.46) | GPR119CHEK2HDAC1 | |
| SCHEMBL241130 | 0.85 | GPR119 (0.59) | GPR119CHEK2HDAC1SLC2A1 | |
| SCHEMBL28612285 | 0.84 | SLC2A1 (0.48) | GPR119CHEK2HDAC1EPHX2SLC2A1 | |
| SCHEMBL31336458 | 0.84 | CHEK2 (0.45) | GPR119CHEK2EPHX2 | |
| SCHEMBL31330775 | 0.81 | GPR119 (0.54) | GPR119CHEK2HDAC1SLC2A1 | |
| SCHEMBL2811017 | 0.79 | SLC2A1 (0.57) | GPR119CHEK2HDAC1SLC2A1 | |
| SCHEMBL27392260 | 0.79 | HDAC1 (0.50) | GPR119CHEK2HDAC1SLC2A1 | |
| SCHEMBL15539025 | 0.78 | GPR119 (0.60) | GPR119CHEK2HDAC1SLC2A1 | |
| SCHEMBL29716381 | 0.78 | GPR119 (0.55) | GPR119CHEK2HDAC1SLC2A1MAPT | |
| SCHEMBL18818429 | 0.78 | GPR119 (0.61) | GPR119CHEK2HDAC1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| EP-3882239-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2021-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | PIM1, PIM3, PIM2 | GPR119 3488/4885CHEK2 4775/4885HDAC1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.